Company Overview
Snapshot
Founded in June 2022 by Vladislav Krupalnik, RenewalBIO operates with 11–50 employees. The company has secured funding across two rounds from four investors, with its May 2025 funding round being the most recent.
Business overview
RenewalBIO is a Health Tech & Life Sciences company focused on addressing critical health challenges such as organ shortages, declining fertility, and degenerative diseases. The company's core technology involves developing replacement cell therapies for human regenerative medicine and fertility. Its R&D team studies ex-vivo and ex-utero post-implantation embryoid models to understand gastrulation and organ formation, and is developing human patient-specific stem-cell derived embryoid models (SEM) grown in a controlled ex-utero device. RenewalBIO's approach aims to optimize iPSC differentiation protocols for various mature cell types, which can then be used for transplantation, disease modeling, and drug studies, serving the biotechnology, life sciences, and pharmaceutical sectors.
Log in to access full profile ›Company Intelligence Q&A
- When was RenewalBIO founded and by whom?
- RenewalBIO was founded in June 2022 by Vladislav Krupalnik.
- What is RenewalBIO's primary focus in the Health Tech & Life Sciences sector?
- RenewalBIO focuses on developing replacement cell therapies for human regenerative medicine and fertility, aiming to address issues like organ shortages, decreasing fertility, degenerative diseases, and aging.
- What is RenewalBIO's employee count?
- RenewalBIO currently has 11–50 employees.